A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

Eli Casdin Biography and Net Worth

Director of Century Therapeutics

Mr. Eli Casdin is the Director of Century Therapeutics.

What is Eli Casdin's net worth?: The estimated net worth of Eli Casdin is at least $3.71 million as of May 19th, 2023. Mr. Casdin owns 1,200,000 shares of Century Therapeutics stock worth more than $3,708,000 as of April 19th. This net worth estimate does not reflect any other investments that Mr. Casdin may own. Learn More about Eli Casdin's net worth.
How do I contact Eli Casdin?: The corporate mailing address for Mr. Casdin and other Century Therapeutics executives is , , . Century Therapeutics can also be reached via phone at 267-817-5790 and via email at [email protected]. Learn More on Eli Casdin's contact information.
Has Eli Casdin been buying or selling shares of Century Therapeutics?: Eli Casdin has not been actively trading shares of Century Therapeutics in the last ninety days. Most recently, on Tuesday, June 22nd, Eli Casdin bought 750,000 shares of Century Therapeutics stock. The stock was acquired at an average cost of $20.00 per share, with a total value of $15,000,000.00. Learn More on Eli Casdin's trading history.
Who are Century Therapeutics' active insiders?: Century Therapeutics' insider roster includes Eli Casdin (Director), and Osvaldo Flores (Pres). Learn More on Century Therapeutics' active insiders.
Are insiders buying or selling shares of Century Therapeutics?: During the last year, insiders at the sold shares 3 times. They sold a total of 25,509 shares worth more than $127,634.86. The most recent insider tranaction occured on March, 7th when insider Adrienne Farid sold 22,831 shares worth more than $117,351.34. Insiders at Century Therapeutics own 7.6% of the company. Learn More about insider trades at Century Therapeutics.
Information on this page was last updated on 3/7/2024.

Eli Casdin Insider Trading History at Century Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/22/2021	Buy	750,000	$20.00	$15,000,000.00

Eli Casdin Buying and Selling Activity at Century Therapeutics

Century Therapeutics Company Overview

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Today's Range

Now: $3.09

$2.91

$3.20

50 Day Range

MA: $4.19

$2.84

$5.32

2 Week Range

Now: $3.09

$1.28

$5.51

Volume

112,750 shs

Average Volume

204,043 shs

Market Capitalization

$200.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.33

SHOCKING Crypto Leak…

From Crypto 101 Media | Ad